OXFORD - Novo Nordisk A/S, one of the world's most established bioscience companies, is linking up with Maxygen Inc., one of the youngest companies, to develop the next generation of industrial enzymes and proteins. The companies have entered a licensing agreement and five-year R&D collaborative program to combine their respective DNA shuffling technologies.

The partners, which declined to reveal the financial terms of the arrangement, will combine their complementary technologies in the area of directed evolution. Novo Nordisk (Bagsvaerd, Denmark) has been developing an in vivo system of gene shuffling in yeast, while Maxygen